PTCT:NASDAQ
PTC Therapeutics, Inc.
$63.70
arrow_upward
+0.08%(+0.050) 1D
$63.70
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 6, 4:00:00 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for PTCT...
Open
$64.53
High
$65.27
Low
$62.92
Mkt. cap
5.30B
Avg. vol.
1.10M
Volume
40.00
52-wk high
$90.87
52-wk low
$61.23
EPS
-$0.56
Beta
0.49
Shares outstanding
83.46M
No. of employees
991
Open
$64.53
High
$65.27
Low
$62.92
Mkt. cap
5.30B
Avg. vol.
1.10M
Volume
40.00
52-wk high
$90.87
52-wk low
$61.23
EPS
-$0.56
Beta
0.49
Shares outstanding
83.46M
No. of employees
991
News stories
From web sources and news partners
Investing.com Canada
·
12 minutes ago
RBC Capital reiterates PTC Therapeutics stock rating at Sector Perform By Investing.com
AD HOC NEWS
·
8 hours ago
Cantor raises target for PTC Therapeutics stock to USD 137.00
Profile
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019. Wikipedia
About PTC Therapeutics, Inc.
CEOMatthew B. Klein
Employees991
FoundedJan 1, 1998
HeadquartersWarren, New Jersey, United States
SectorBiotechnology
Websiteptcbio.com